copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
FDA approves nivolumab with ipilimumab for colorectal cancer The FDA also converted the accelerated approval to regular approval for single agent nivolumab for adult and pediatric patients 12 years of age and older with MSI-H or dMMR metastatic CRC, that
Drugs Approved for Colon and Rectal Cancer - NCI This page lists cancer drugs approved by the Food and Drug Administration (FDA) for use in colon cancer and rectal cancer The list includes generic names, brand names, and common drug combinations, which are shown in capital letters
Current Targeted Therapy for Metastatic Colorectal Cancer Abstract Colorectal cancer (CRC) is the third most common type of cancer and the second leading cause of cancer deaths worldwide Surgery or surgery plus radiotherapy and or chemotherapy for patients with metastatic CRC (mCRC) were accepted as the main therapeutic strategies until the early 2000s, when targeted drugs, like cetuximab and bevacizumab, were developed The use of targeted drugs in
FDA APPROVES LUMAKRAS® (SOTORASIB) IN COMBINATION WITH . . . In June 2017, the FDA approved a refined indication for Vectibix for use in patients with wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) mCRC, specifically as first-line therapy in combination with FOLFOX and as monotherapy following disease progression after prior treatment with
U. S. Food and Drug Administration Approves Opdivo® (nivolumab . . . U S Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer
U. S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as . . . This release contains forward-looking information about the BRAFTOVI® (encorafenib) plus cetuximab and mFOLFOX6 combination and a new indication in the U S for the treatment of patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, including their potential benefits and discussions
FDA Oks Sotorasib Panitumumab in KRAS G12C-Mutant Colorectal . . . The approval of this combination is supported by data from the phase 3 CodeBreaK 300 study The FDA has approved the combination of sotorasib (Lumakras) and panitumumab (Vectibix) for the treatment of patients with previously treated KRAS G12C-mutated metastatic colorectal cancer (CRC) The approval